Responses

We Need to Talk About Codeine: an Implementation Study to reduce the number of Emergency Department patients discharged on high-strength co-codamol using the Behaviour Change Wheel
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Maybe codeine's pharmacokinetics are an issue too
    • Paul Tanto, Adult EM & PEM consultant London North West University Healthcare NHS Trust

    A well timed project with the contemporary interest in the subject of drug misuse in Scottish politics, and also with the recent airing of Dopesick on streaming services about the US experience.

    I wonder whether the known CYP2D6 polymorphism leading to poor metabolism of codeine has a role in the increase of opioid prescriptions? Mikus and Weiss (2005) state that 5-10% of Caucasian have severely impaired metabolism of codeine and that a further 10-15% show some impairment. This means up to 1 in 4 Caucasians don't get a full analgesic effect from codeine.

    Maybe we are seeing a lessening of patients putting up with their lot of suboptimal pain control? And in turn an increase in prescriptions to accommodate that demand.

    Dihydrocodeine by contrast doesn't have the same issues with metabolism and ineffective analgesia. While acknowledging the past issues when DF118s were misused, perhaps prescribing dihydrocodeine instead of codeine we'll see better analgesia in our patients and perhaps a reduction in demand for prescriptions?

    Mikus G and Weiss J. (2005) 'Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response', Current Pharmacogenomics, 3, pp43-52

    Conflict of Interest:
    None declared.